Seroconversion and booster effect of the BBIBP-CorV vaccine (Sinopharm) in health personnel of a private laboratory in Lima, Peru

Published: 5 January 2022| Version 2 | DOI: 10.17632/mnjnh69jsg.2
Jose Alonso Caceres Del Aguila


This database corresponds to the results from all the health workers from a private laboratory, who have worked during the pandemic period, and had received two doses of the BBIBP-CorV vaccine (Sinopharm). The serological evaluation was performed employing the Elecys® anti-SARS-CoV-2 S and the cPass™ SARS-CoV-2 Neutralization Antibody Detection kit during the first 21, 90, and 180 days after the second dose.



Immunology, Vaccine, Immunoassay, Enzyme-Linked Immunosorbent Assay, Neutralizing Antibody, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19